Humana faces significant earnings headwinds due to CMS reforms, star rating downgrades, and potential Medicaid clawbacks.

Humana’s stock performance and market strategies continue to be closely monitored by investors and analysts, with particular attention to how the company navigates industry challenges.

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

While robust first-quarter earnings and operational performance were reported ... Unlock comprehensive insights into our analysis of Humana stock in this financial health report.

Raymond (NSE:RYMD) James has upgraded Humana’s stock rating from Market Perform to Outperform, setting a new price target of $315, citing the company’s strong performance and favorable drug mix.

Shares of Humana Inc. rallied 3.94% to $247.34 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 0.09% to 5,963.60 and the Dow ...

Per WSJ’s forecasting data, the average UNH price target is $378.86 per share. Given that the current UNH price is $292.80 per share, this gives investors a profit potential of 30%. The bottom ...

Per WSJ’s forecasting data, the average UNH price target is $378.86 per share. Given that the current UNH price is $292.80 ...